Citizens Upgrades Allogene Therapeutics to Outperform
Citizens upgraded Allogene Therapeutics to Outperform with a $5 target, citing improved trial visibility and strong long-term sales potential for cema-cel.
/ 2 items
Citizens upgraded Allogene Therapeutics to Outperform with a $5 target, citing improved trial visibility and strong long-term sales potential for cema-cel.
JPMorgan cuts Allogene Therapeutics rating to Underweight after company removes CD52 component from cema-cel treatment following fatal event. Near-term outlook remains "challenging."